Company / Revenue
Aclaris Therapeutics, Inc. Revenue History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$7.8M
FY2025
5-year range
$6.8M / $31.2M
FY2021-FY2025
Trend
-75.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has fluctuated over the past 9 years, ranging from $2M in FY2019 to $31M in FY2024.
Based on SEC 10-K filings.
$8M in FY2025 with a 5-year CAGR of +4.9%.
Improved from $7M to $8M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -35.9%
- 5-Year CAGR
- +4.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +4.9%, indicating consistent growth.
- In FY2025, revenue decreased 75.0% year-over-year.
- Peak revenue was recorded in FY2024.
- Lowest revenue in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.8M | -75.0% |
| FY2024 | $31.2M | +362.2% |
| FY2023 | $6.8M | -77.3% |
| FY2022 | $29.8M | +340.1% |
| FY2021 | $6.8M | +9.9% |
| FY2020 | $6.2M | +265.5% |
| FY2019 | $1.7M | -72.6% |
| FY2018 | $6.2M | +265.5% |
| FY2017 | $1.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026